Janux Therapeutics Inc JANX:NASDAQ

RT Quote | NASDAQ | USD
Last | 09/30/22 EDT
13.54quote price arrow up+0.17 (+1.27%)
Volume
39,353
52 week range
9.39 - 29.51
Loading...
  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close13.54
  • 52 Week High29.51
  • 52 Week High Date11/08/21
  • 52 Week Low9.39
  • 52 Week Low Date05/09/22

Key Stats

  • Market Cap564.08M
  • Shares Out41.66M
  • 10 Day Average Volume0.06M
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-31.37

KEY STATS

  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close13.54
  • 52 Week High29.51
  • 52 Week High Date11/08/21
  • 52 Week Low9.39
  • 52 Week Low Date05/09/22
  • Market Cap564.08M
  • Shares Out41.66M
  • 10 Day Average Volume0.06M
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-31.37

RATIOS/PROFITABILITY

  • EPS (TTM)-1.32
  • P/E (TTM)-10.27
  • Fwd P/E (NTM)-6.90
  • EBITDA (TTM)-54.916M
  • ROE (TTM)-14.95%
  • Revenue (TTM)6.73M
  • Gross Margin (TTM)-
  • Net Margin (TTM)-809.63%
  • Debt To Equity (MRQ)0.00%

EVENTS

  • Earnings Date11/09/2022(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Janux Therapeutics Inc

 

Content From Our Affiliates

There is no recent news for this security.

Profile

MORE
Janux Therapeutics, Inc. is a biopharmaceutical company that is engaged in developing a pipeline of immunotherapies by applying its technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms to treat patients suffering from cancer. The Company's initial focus is on developing a class of T cell engagers (TCEs), and its lead product candidates are designed to target clinically validated drug targets. It is developing a...
Jay Lichter Ph.D.
Chairman of the Board
David Campbell Ph.D.
President, Chief Executive Officer, Founder, Director
Tighe Reardon CPA
Acting Chief Financial Officer
Address
10955 Vista Sorrento Parkway, Suite 200
San Diego, CA
92130
United States

Top Peers

SYMBOLLASTCHG%CHG
IPSC
Century Therapeutics Inc
9.89-0.12-1.20%
VERA
Vera Therapeutics Inc
21.31+0.44+2.11%
VRDN
Viridian Therapeutics Inc
20.51+0.57+2.86%
ALT
Altimmune Inc
12.77+0.15+1.19%
CGEM
Cullinan Oncology Inc
12.82+0.38+3.05%